Repare Therapeutics: New Data Highlights Urgent Need for Innovative Gynecologic Cancer Treatments
Monday, Sep 23, 2024 7:15 am ET
1min read Repare Therapeutics, a leading clinical-stage precision oncology company, has recently announced new data underscoring the urgent need for additional treatment solutions for patients with metastatic gynecologic cancers. The findings, presented at the American Association for Cancer Research (AACR) Ovarian Cancer Research Symposium, highlight the impact of specific biomarkers on patient outcomes and the potential of Repare's pipeline to address these unmet medical needs.
The analysis of approximately 2,000 patients revealed that those with certain biomarkers, such as FBXW7, PPP2R1A, and CCNE1 alterations (Lunre BM+), had significantly reduced median overall survival (mOS) compared to patients without these biomarkers (Lunre BM-). In ovarian cancer, Lunre BM+ patients had a 28% decrease in mOS, while in endometrial cancer, the decrease was 27%. These findings emphasize the critical need for innovative treatments tailored to patients with these biomarkers.
Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biomarkers, with data expected in the fourth quarter of 2024. This trial aims to address the unmet medical need for patients with metastatic gynecologic cancers and improve their overall survival.
The analysis of approximately 2,000 patients revealed that those with certain biomarkers, such as FBXW7, PPP2R1A, and CCNE1 alterations (Lunre BM+), had significantly reduced median overall survival (mOS) compared to patients without these biomarkers (Lunre BM-). In ovarian cancer, Lunre BM+ patients had a 28% decrease in mOS, while in endometrial cancer, the decrease was 27%. These findings emphasize the critical need for innovative treatments tailored to patients with these biomarkers.
Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biomarkers, with data expected in the fourth quarter of 2024. This trial aims to address the unmet medical need for patients with metastatic gynecologic cancers and improve their overall survival.
